The FDA said moving forward, it will adopt a framework requiring proof that a vaccine can generate antibodies in people over the age of 65 years and for all persons above the age of 6 months with

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip.

A change in recommending Covid vaccines for children and pregnant women would circumvent an expert panel but please many MAHA fans.

Leaders at the FDA, HHS and elsewhere are putting guardrails around COVID-19 boosters, which could mean delayed shots or eligibility changes this fall.

The Wall Street Journal reports HHS is expected to stop recommending routine Covid shots for children and pregnant women. This as new testing requirements could delay the availability of shots. Dr. Kavita Patel joins Ayman Mohyeldin on The 11th Hour.

Since the COVID-19 pandemic, there has been a decline in U.S. vaccine uptake, while widespread misinformation and distrust make it challenging to craft effective public health responses.

The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that the agency could update its vaccine approval guidelines “in the coming days.”